|
|
||||||||
1 Sealy Center for Molecular Cardiology and 2 Department of Human Biological Chemistry and Genetics and 3 Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555
| |
ABSTRACT |
|---|
|
|
|---|
Interleukin (IL)-6 reportedly has negative
inotropic and hypertrophic effects on the heart. Here, we describe
endotoxin-induced IL-6 in the heart that has not previously been well
characterized. An intraperitoneal injection of a bacterial
lipopolysaccharide into C57BL/6 mice induced IL-6 mRNA in the heart
more strongly than in any other tissue examined. Induction of mRNA for
two proinflammatory cytokines, IL-1
and tumor necrosis factor
(TNF)-
, occurred rapidly before the induction of IL-6 mRNA and
protein. Although stimulation of isolated rat neonatal myocardial cells
with IL-1
or TNF-
induced IL-6 mRNA in vitro, nonmyocardial heart
cells produced higher levels of IL-6 mRNA upon stimulation with
IL-1
. In situ hybridization and immunohistochemical analyses
localized the IL-6 expression primarily in nonmyocardial cells in vivo.
Endotoxin-induced expression of cardiac IL-1
, TNF-
, and
intercellular adhesion molecule 1 was augmented in IL-6-deficient mice
compared with control mice. Thus cardiac IL-6, expressed mainly by
nonmyocardial cells via IL-1
action during endotoxemia, is likely to
suppress expression of proinflammatory mediators and to regulate itself via a negative feedback mechanism.
heart; cytokines; inflammation; sepsis; interleukin 6-knockout mice
| |
INTRODUCTION |
|---|
|
|
|---|
INTERLEUKIN (IL)-6 is
a multifunctional cytokine produced by a wide variety of cells and is
known to play important roles in immunological responses,
hematopoiesis, host defense, and acute phase reaction (1).
IL-6 is a member of the family of cytokines that includes IL-11,
leukemia inhibitory factor, ciliary neurotrophic factor, oncostatin M,
and cardiotrophin 1. These cytokines share glycoprotein (gp) 130 as a
common singling subunit for their receptors and transduce their signals
through the Janus kinase (JAK)-signal transduction and activation of
transcription (STAT) and Ras-mitogen-activated protein kinase (MAPK)
nuclear factor (NF)/IL-6 pathways. A number of acute phase
response genes contain binding sites for STAT and/or NF/IL-6
transcription factors [such as CCAAT/enhancer binding protein
(C/EBP)-
] in their promoters and are induced by IL-6 through the
gp130 pathways (11, 15).
The role of IL-6 in the heart is complex. IL-6 may be involved in cardiac hypertrophy, because activation of gp130 signaling has been shown to cause cardiac hypertrophy in transgenic mice; furthermore, treatment of neonatal rat myocardial cells together with IL-6 and its soluble receptor induced myocardial hypertrophy in vitro (12). IL-6 mRNA is reportedly induced in the myocardium of a canine model of ischemia and reperfusion (3, 18). The plasma levels of IL-6 are elevated in patients with either acute myocardial infarction (14) or sepsis, and IL-6 is considered by some to be the cytokine best correlated with the severity of sepsis (20). Because IL-6 reportedly exerts a negative inotropic effect on hamster papillary muscle and human heart pectinate muscle (7, 8), IL-6 may play a role in the depression of myocardial contractility in sepsis or myocardial infarction.
Whereas induction of IL-6 after ischemia-reperfusion has been well
documented (3, 10, 18), little is known about its expression during sepsis/endotoxemia. In the present study, we characterized the endotoxin-induced expression of cardiac IL-6 in a
mouse model by localizing its expression primarily in nonmyocardial cells and defining IL-1
as a major mediator of the expression. With
the use of IL-6-deficient mice, we also demonstrate a possible role for
IL-6 as a downregulator of proinflammatory mediators in the heart
during endotoxemia.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals.
Four-month-old male C57BL/6 mice (28.5 ± 2.0 g body wt) were
purchased from Charles River Laboratories (Wilmington, MA).
Two-month-old male IL-6-deficient (
/
) mice (17) and
control (+/+) mice were obtained from the Jackson Laboratory (Bar
Harbor, ME) and used when they became 4 mo old. The genetic background
of these mice was either B6x129 or C57BL/6. Three-month-old male
Sprague-Dawley rats (275-310 g body wt) were purchased from Harlan
Sprague Dawley (Indianapolis, IN). Before the experiments were
conducted, the animals were kept at least 10 days in a 12-h light cycle
and fed a standard chow diet ad libitum. Animals were injected
intraperitoneally with bacterial lipopolysaccharide (LPS) derived from
Pseudomonas aeruginosa (Sigma Chemical, St. Louis, MO) and
dissolved in physiological saline solution. At the indicated time
points, animals were killed by cervical dislocation, blood was
collected by decapitation, and tissues were quickly dissected. Except
for the LPS-dose-response experiment, mice were injected with 50 µg
(1.8 mg/kg body wt) of LPS. None of the mice died after injection with
this dose of LPS. All procedures have been approved by the University
of Texas Medical Branch Institutional Animal Care and Use Committee.
Northern blot analysis.
Each excised heart was quickly cross cut into four pieces, blotted onto
paper towels to remove excess blood, transferred into a cryovial,
rapidly frozen in liquid nitrogen, and stored at
80°C. The
frozen tissues were individually transferred into guanidine-phenol solution and processed with a tissue homogenizer (Polytron PT3000, Brinkmann Instruments, Westbury, NY), and the total RNA was isolated by
the method of Chomczynski and Sacchi (5). The RNA samples (20 µg) were electrophoretically fractionated through 1.0% agarose gels containing 3% formaldehyde buffered in 20 mM MOPS and 1 mM EDTA
at pH 7.4. The integrity of the RNA and the equality of loading were
verified by the intensities of rRNA in ethidium bromide-stained gels.
The RNAs were transferred overnight from the gels to Zeta-Probe nylon
membranes (Bio-Rad Laboratories, Hercules, CA) and fixed by ultraviolet
cross-linking. Radiolabeled probes were prepared from mouse cDNA by the
random priming technique with [
-32P]dCTP using
Megaprime DNA labeling systems RPN 1606 (Amersham Pharmacia,
Piscataway, NJ). DNA plasmids containing the mouse IL-1
and IL-6
cDNA (pMuIL-1
and pcD-mIL-6, respectively) were obtained from Dr. D. Pennica (see Ref. 9) and Dr. F. Lee (see Ref. 4), respectively. The
plasmid K3-1.1 containing the mouse intercellular adhesion
molecule (ICAM)-1 cDNA was purchased from American Type Culture
Collection (Rockville, MD). For the tumor necrosis factor (TNF)-
probe, a 326-bp cDNA fragment was amplified by RT-PCR using 1 µg of
total heart RNA from a mouse that was injected with LPS 6 h before
being killed. The primer sequences and reaction condition of the RT-PCR
were described previously (23). The PCR product was
agarose gel purified and used directly for radiolabeling. The methods
for hybridization and washing were described by Church and Gilbert
(6). Because all of the cDNA probes were derived from
mice, the hybridization and washing were performed under stringent
conditions (at 65°C) for detecting mouse mRNA or under less stringent
conditions (at 60°C) for detecting rat mRNA. The washed filters were
exposed to Kodak XAR-5 film in the presence of an intensifying screen
at
80°C. As a control, the filters were reprobed with radiolabeled
DNA specific for the 18S ribosomal subunit. The relative amounts of RNA
were determined by densitometric analysis of Northern blot
autoradiograms using a scanning, transmitting densitometer. The levels
of mRNA for cytokines were normalized to the 18S RNA signals.
Isolation of cytoplasmic proteins from mouse hearts and cytokine
measurements.
A previously described method for isolating nuclear proteins from mouse
brains (23) was modified to isolate cytoplasmic proteins
from mouse hearts. Each heart was quickly minced into at least 50 small
pieces with a razor blade in ice-cold Tris-buffered saline [25 mM
Tris · HCl (pH 7.4), 5 mM KCl, and 137 mM NaCl]. The tissue
pieces were rinsed with the buffer to remove blood and then processed
in a Dounce homogenizer (Kontes Glass, Vineland, NJ) with 2 ml of
ice-cold buffer A including proteinase inhibitors and
phosphatase inhibitors (23). Homogenates were left on ice for 15 min, a volume of 10% Nonidet P-40 was then added (final concentration 0.6%), and the samples were centrifuged at 3,000 g for 10 min at 4°C. The supernatants (cytoplasmic
fraction) were aliquoted and stored at
80°C. The protein
concentrations were determined using protein assay reagent (Bio-Rad
Laboratories). The cytokine concentrations in the samples were
determined by ELISA using ELISA kits specific for mouse cytokines that
were purchased from Endogen (Woburn, MA).
In vitro cell culture. Primary cultures of cardiac cells were prepared essentially by the method of Simpson (24). The left ventricles from 1- to 2-day-old Sprague-Dawley rat pups were minced and subjected to serial trypsin-collagenase digestion (0.125%-0.025%, respectively) to release single cells. After the cells underwent the final digestion, the cells were washed and plated for 30 min in medium 199 with 10% fetal bovine serum. Nonattached cells (the myocyte-enriched population) were counted and replated in 100-mm Corning dishes at 4 × 106 cells/plate in the same medium with cytosine arabinofuranoside (5 µg/ml), insulin (10 µg/ml), transferrin (10 µg/ml), and penicillin (50 U/ml). Cells attached to the dish within the 30 min of the initial plating were taken as the nonmyocyte-enriched population. Two days later, the cultures were used for experiments. With this protocol, we usually obtained the myocyte-enriched cultures with ~80% cells beating. The nonmyocyte-enriched cultures contained <1% beating cells.
Immunohistochemistry. Mouse hearts were cut horizontally into halves, and cryosections were prepared. The sections were incubated overnight at 4°C with polyclonal rabbit anti-rat IL-6 antibody SC-1267 (Santa-Cruz Biotechnology, Santa Cruz, CA). After they were serially washed with phosphate-buffered saline, the slides were incubated with biotinylated secondary antibody for 45 min at room temperature. The sections were developed with ABC reagent (ABC kit, Vector Laboratories, Burlingame, CA) for 45 min. After they were incubated in Fast Red (Sigma Chemical, F-4648) containing 1 mM levamisole, the slides were counterstained with Mayer-hematoxylin and mounted for light microscopy (22).
In situ hybridization. Heart tissues were fixed in 4% paraformaldehyde for 12 h and embedded in paraffin. The embedded tissues were cut into 5-µm thick sections and dried on glass slides at 37°C overnight, followed by dewaxing and rehydration. Slides were incubated with proteinase K (2.5 µg/ml, Sigma) in 100 mM Tris · HCl (pH 7.6) and 10 mM EDTA for 30 min at 37°C and then in 0.25% acetic anhydride in 0.1 M triethanlamine (pH 8.0) for 10 min, followed by dehydration and air-drying. The mouse IL-6 cDNA probe was labeled using the MAXIscript kit (Ambion, Austin, TX) and [35S]UTP to generate sense and antisense riboprobes. Hybridization with the sense strand served as a control. Hybridization was performed at 55°C for 12 h as described (22). The slides were dehydrated and first exposed to Kodak XAR-5 film for 3 days. For microautoradiography, the slides were then coated with NTB2 emulsion (Eastman Kodak, New Haven, CT), exposed in the dark for 2 wk, and counterstained with hematoxylin and eosin. All sections were examined by bright- and dark-field microscopy.
| |
RESULTS |
|---|
|
|
|---|
Endotoxin-induced IL-6 mRNA in hearts and other tissues.
IL-6 mRNA was not detectable in the hearts of untreated and
saline-injected mice by Northern blot analyses. Three hours after the
mice were injected with LPS, IL-6 mRNA was strongly induced in the
mouse heart. The induced levels increased in a dose-dependent fashion
up to a dose of 100 µg of LPS (3.5 mg/kg body wt) and did not
increase further with >100 µg of LPS (Fig.
1A). For the rest of the mouse
studies, a nonlethal dose of 50 µg (1.8 mg/kg body wt) was chosen,
and noninjected mice were used as controls.
|
IL-1
and TNF-
as mediators for induction of cardiac IL-6
during endotoxic shock.
We compared the induction of IL-6 mRNA with those of other inflammatory
mediators, IL-1
, TNF-
, and ICAM-1. With the use of Northern blot
hybridization, we analyzed the RNA from the hearts of mice killed at
0.5, 1, 1.5, 3, and 6 h after LPS injection and from control
noninjected mice. The results shown in Fig.
2 demonstrate that IL-6 mRNA became
detectable at 1 h and peaked at 3 h after LPS injection.
Strong induction of IL-1
mRNA occurred well before that of IL-6,
appearing as early as 0.5 h and peaking at 1 h. TNF-
mRNA
was also detectable at 0.5 h and peaked at 1 h. Unlike these
cytokines, ICAM-1 mRNA was detectable at low levels without LPS
injection (0 h), and the induction occurred at 1 h and peaked at
1.5 h (Fig. 2, A and B). We also measured IL-6 protein levels in the heart over the same time course. Until 1.5 h after the mice were injected with LPS, IL-6 protein levels were very low or below the limits of detection. A rapid increase and
decline of IL-6 protein levels was seen at 3 and 6 h,
respectively, demonstrating that the pattern of IL-6 protein levels
follows IL-6 mRNA levels (Fig. 2C)
|
and IL-1
mRNA precedes that of IL-6, raising the possibility that
these two cytokines stimulate cardiac cells to produce IL-6. We
directly tested this possibility by analyzing IL-6 mRNA expression in
cultured neonatal rat cardiac cells treated with TNF-
or IL-1
in
vitro. Myocytes and nonmyocytes were separated as described in
MATERIALS AND METHODS, and both cultures were analyzed. As shown in Fig. 3, both IL-1
and TNF-
induced IL-6 mRNA in the myocyte cultures in vitro, although induction
by the former was stronger (Fig. 3, lanes 3-5). In the
nonmyocyte cultures, only IL-1
strongly induced IL-6 mRNA, whereas
TNF-
had little effect (Fig. 3, lanes 6-8). Taken
together, our data are consistent with a model whereby the cardiac IL-6
is induced by mediators of inflammation, mainly IL-1
and to a lesser
extent TNF-
, both of which are induced before IL-6 in vivo.
|
Localization of cardiac IL-6 expression during endotoxic shock.
The in vitro cell study demonstrated that IL-6 mRNA is induced in the
nonmyocyte cultures to levels approximately threefold higher than in
myocyte cultures (Fig. 3). This result suggests that cardiac IL-6 mRNA
is expressed mainly in nonmyocyte cells of the heart during endotoxic
shock. To verify this observation in vivo, we performed in situ
hybridization and immunohistochemical analyses to localize cardiac IL-6
mRNA and protein, respectively. Autoradiograms of the in situ
hybridization analysis showed that the induced IL-6 mRNA signals were
evenly distributed in the whole heart (Fig.
4C). The in situ time course
of IL-6 mRNA induction after LPS injection correlated well with the
results of Northern blot analyses (Figs. 2 and 4, A-C).
Through microautoradiography, the strongest signals of IL-6 mRNA were
localized only in nonmyocytes, whereas weaker signals were seen in
myocytes (Fig. 4G). Immunohistochemical analyses detected
IL-6 protein mainly in and around nonmyocytes after LPS injection (Fig.
5). Therefore, we conclude that the induction of cardiac IL-6 during endotoxemia occurs mostly in nonmyocytes.
|
|
Augmented induction of the IL-1
, TNF-
, and ICAM-1 genes in
hearts of IL-6-deficient (
/
) mice.
To elucidate the role of IL-6 in regulating gene expression in the
heart during endotoxemia, we compared the induction of various genes in
the hearts of IL-6-deficient (
/
) mutant mice and non-IL-6-deficient
(+/+) mice. We killed the mice 6 h after they were injected with
LPS and performed Northern blot analyses for mRNA from six
stress-inducible genes: IL-6, IL-1
, TNF-
, ICAM-1, C/EBP-
, and
C/EBP-
. As shown in Fig. 6,
A and B, the LPS-induced IL-6 mRNA was detected
only in non-IL-6-deficient (+/+) mice but not in IL-6-deficient (
/
)
mice, thereby confirming the IL-6-deficient genotype of these mice.
Although the mRNAs for ICAM-1, C/EBP-
, and C/EBP-
were
constitutively detected without LPS injection, there were no
significant differences in the two mouse groups. The induced mRNA
levels for IL-1
, TNF-
, and ICAM-1 were significantly higher in
the hearts of IL-6-deficient (
/
) mice than non-IL-6-deficient (+/+)
mice (2.2-, 2.4-, and 2.5-fold, respectively). The mRNA level for
C/EBP-
and C/EBP-
were also induced in the hearts of both
IL-6-deficient (
/
) and control (+/+) mice after LPS injection, but
there were no significant differences between the two groups. We
further compared protein levels of IL-1
and TNF-
by ELISA in the
hearts of IL-6-deficient (
/
) and control (+/+) mice (both with
C57BL/6 genetic background) 6 h after LPS injection. The levels
for IL-1
and TNF-
were higher in the hearts of IL-6-deficient
(
/
) mice than those in non-IL-6-deficient (+/+) mice (1.8- and
2.8-fold, respectively; Fig. 6C). The augmented induction of
genes for IL-1
, TNF-
, and ICAM-1 in the IL-6-deficient mice
suggests that IL-6 has a role in downregulating the expression of these
three genes in the heart during endotoxemia.
|
| |
DISCUSSION |
|---|
|
|
|---|
Previously, Troutt and Lee (26) detected IL-6 mRNA in the heart, kidney, and spleen but not in the brain, liver, thymus, lung, and bone marrow of mice 3 h after they were intravenously injected with 5 µg of Salmonella typhosa-derived LPS. In the present study, we detected IL-6 mRNA not only in the heart, kidney, and spleen but also in the brain, lung, liver, and skeletal muscle of the mice 3 h after they were intraperitoneally injected with 50 µg of LPS. In both studies, the induced levels of IL-6 mRNA were highest in the heart, suggesting that IL-6 may have a significant biological role in the heart during endotoxemia. The additional detection of IL-6 mRNA in the brain, lung, and liver, which were not found previously, may be due to differences in doses and types of LPS or route of LPS administration.
Through in situ hybridization and immunohistochemistry, we demonstrated
that cardiac IL-6 induction occurs mainly in nonmyocytes during
endotoxemia. These results are distinct from IL-6 induction after
myocardial infarction, in which IL-6 is induced in both the myocardium
and in infiltrating mononuclear cells (10). Induction of
IL-6 by IL-1
or TNF-
in cultured myocytes in vitro has been demonstrated previously (10, 29). However, new findings in the present study demonstrated that nonmyocytes respond to IL-1
with
an induction of IL-6 mRNA and, more importantly, that this response is
approximately threefold stronger compared with that of myocytes. Thus
these results strongly support our interpretation of these in vivo
observations that the nonmyocyte is the predominant cell type that
expresses IL-6 in the heart during endotoxemia. However, myocytes also
express IL-6 at low levels during endotoxemia. We detected this as weak
IL-6 mRNA signals in myocytes by in situ hybridization as well as
through a moderate induction of IL-6 mRNA that occurred in myocytes in
vitro after stimulation with either IL-1
or TNF-
. It was
intriguing that TNF-
at 10 ng/ml concentration moderately induced
IL-6 mRNA in myocytes but not in nonmyocytes. These results suggest
that cytokine-mediated stress responses exhibit differential levels of
sensitivity to LPS in myocytes versus nonmyocytes. This may be due to
differences in the number of cytokine receptors on these cells. The
cardiac nonmyocytes include fibroblasts, macrophages, vascular
endothelial cells, and smooth muscle cells. All of these cells are
known to express IL-6 in certain conditions (1, 16).
Further study will be required to identify which of these cell types
express IL-6 in the heart during endotoxic stress.
Because IL-6 is induced together with IL-1
and TNF-
and is a
strong activator of hepatic acute phase response (2), it has been classified as a proinflammatory cytokine. However, several studies have suggested that IL-6 may play a role in the downregulation of other proinflammatory genes. For example, IL-6 has been reported to
suppress LPS-induced TNF-
in serum or IL-1
mRNA levels in the
liver and spleen in mice (27). More recently, it was
reported that induction of TNF-
and macrophage inflammatory protein
2 during acute lung inflammation is higher in IL-6-deficient
(
/
) mice than in non-IL-6-deficient (+/+) mice, suggesting that
IL-6 downregulates these inflammatory genes (28). In the
present study, we used a similar approach by using IL-6-deficient
(
/
) mice to seek a role for IL-6 in suppressing inflammatory genes in the heart. We showed that LPS-induced mRNA levels for three inflammatory genes (IL-1
, TNF-
, and ICAM-1) were significantly higher in the hearts of IL-6-deficient (
/
) mice than those of non-IL-6-deficient (+/+) mice, suggesting that IL-6 functions to
negatively regulate the expression of these three genes. Both IL-1
and TNF-
cause myocardial depression (19) and also
induce ICAM-1 gene expression (25). ICAM-1 promotes
neutrophil-myocyte adhesion that may cause cardiac cell injury and/or
necrosis due to the cytotoxic activity of the neutrophils
(30). Therefore, IL-6 may play a cardioprotective role
during endotoxemia by downregulating ICAM-1 expression. Furthermore,
IL-6 is likely to self-regulate its expression by suppressing its own
inducers, IL-1
and TNF-
.
It has been reported that ICAM-1 is induced by IL-1
, TNF-
(25), or IL-6 (30) in cultured myocytes. It
was also reported that peak IL-6 mRNA induction precedes that of ICAM-1
mRNA in a canine model of myocardial ischemia and reperfusion,
supporting the idea that IL-6 is important in the induction of ICAM-1
in the area of ischemia (18). However, our time course
study showed that LPS-mediated induction of ICAM-1 mRNA occurs later
than that of IL-1
and TNF-
mRNA and slightly earlier than that of
IL-6 mRNA (Fig. 2). These results suggest that the major inducers of cardiac ICAM-1 during endotoxemia are IL-1
and/or TNF-
rather than IL-6. Furthermore, our studies using IL-6-deficient (
/
) mice
demonstrated that the cardiac ICAM-1 mRNA is induced more strongly in
IL-6-deficient (
/
) mice than in non-IL-6-deficient (+/+) mice,
suggesting that IL-6 is not an essential inducer of ICAM-1 but rather a
suppressor during endotoxemia (Fig. 6). Taken together, our data
suggest that the cardiac inflammation cascade during endotoxemia is not
the same as that in ischemia-reperfusion.
The molecular mechanisms for downregulation of the three inflammatory
genes (IL-1
, TNF-
, and ICAM-1) by IL-6 remain unclear. IL-6 can
activate the transcription factors STAT-3 or C/EBP-
(or NF/IL-6) via
the gp130/JAK-STAT or Ras-MAPK-NF/IL-6 pathway, respectively. Because a
NF/IL-6 (or C/EBP-
) binding site is present in the ICAM-1 gene
regulatory region (13), C/EBP-
may be activated by IL-6
and, in turn, downregulate the ICAM-1 gene. Alternatively, IL-6 may
indirectly downregulate ICAM-1 by suppressing IL-1
and TNF-
,
which are the direct inducers of ICAM-1 (25).
Although the C/EBP-
gene is reportedly induced by IL-6
(21), there was no decrease in the induced C/EBP-
mRNA
levels in the hearts of IL-6-deficient (
/
) mice after LPS
administration (Fig. 6). This result suggests that IL-6 deficiency is
ameliorated by other cytokines for induction of the C/EBP-
gene.
Whereas a number of hepatic acute phase response genes are known to be induced by endotoxin challenge and by IL-6 (1, 2, 11), little is known about gene expression in response to endotoxin or IL-6
in the heart. Further studies screening expression of multiple genes
are necessary to further understand the effects of endotoxin or IL-6 in
the heart.
In conclusion, IL-6 is strongly induced in the heart during endotoxic
stress, and nonmyocardial cells are the primary source of the cardiac
IL-6. The IL-6 expression is induced mainly by IL-1
, which is also
induced in the heart earlier during endotoxic shock. The
endotoxin-induced IL-6 is likely to downregulate expression of IL-1
,
TNF-
, and ICAM-1 in the heart, suggesting a self-regulatory mechanism and a possible anti-inflammatory function for IL-6.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. D. Pennica and F. Lee for providing the mouse cDNA
clones for IL-1
and IL-6 cDNA, respectively. We thank Suzhen Li for
technical assistance in cell isolation. We also thank Drs. H. Shimomura
and D. A. Konkel for technical discussion and critically reading
the manuscript, respectively.
| |
FOOTNOTES |
|---|
This work was supported by a Grant-In-Aid 97G-654 from the American Heart Association, Texas Affiliate, the Seed Money from the Sealy Center on Aging, University of Texas Medical Branch (to H. Saito), and Grant 2-P01-AG10514 from the National Institute on Aging (to J. Papconstantinou; Publication No. 107).
Address for reprint requests and other correspondence: H. Saito, Dept. of Human Biological Chemistry and Genetics, Univ. of Texas Medical Branch, Galveston, TX 77555-0643 (E-mail: hsaito{at}utmb.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 17 December 1999; accepted in final form 17 May 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Akira, S,
and
Kishimoto T.
IL-6 and NF-IL6 in acute-phase response and viral infection.
Immunol Rev
127:
25-50,
1992[ISI][Medline].
2.
Castell, JV,
Gomez-Lechon MJ,
David M,
Andus T,
Geiger T,
Trullenque R,
Fabra R,
and
Heinrich P.
Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes.
FEBS Lett
242:
237-239,
1989[ISI][Medline].
3.
Chandrasekar, B,
Mitchell DH,
Colston JT,
and
Freeman GL.
Regulation of CCAAT/enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion.
Circulation
99:
427-433,
1999
4.
Chiu, CP,
Moulds C,
Coffman RL,
Rennick D,
and
Lee F.
Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells.
Proc Natl Acad Sci USA
85:
7099-7103,
1988
5.
Chomczynski, P,
and
Sacchi N.
Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction.
Anal Biochem
262:
8409-8415,
1987.
6.
Church, GM,
and
Gilbert W.
Genomic sequencing.
Proc Natl Acad Sci USA
81:
1991-1995,
1984
7.
Finkel, MS,
Oddis CV,
Jacob TD,
Watkins SC,
Hattler BG,
and
Simmons RL.
Negative inotropic effects of cytokines on the heart mediated by nitric oxide.
Science
257:
387-389,
1992
8.
Finkel, MS,
Hoffman RA,
Shen L,
Oddis CV,
Simmons RL,
and
Hattler BG.
Interleukin-6 (IL-6) as a mediator of stunned myocardium.
Am J Cardiol
71:
1231-1232,
1993[ISI][Medline].
9.
Gray, PW,
Glaister D,
Chen E,
Goeddel DV,
and
Pennica D.
Two interleukin 1 genes in the mouse: cloning and expression of the cDNA for murine interleukin 1
.
J Immunol
137:
3644-3648,
1986[Abstract].
10.
Gwechenberger, M,
Mendoza LH,
Youker KA,
Frangogiannis NG,
Smith CW,
Michael LH,
and
Entman ML.
Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions.
Circulation
99:
546-551,
1999
11.
Heinrich, PC,
Behrmann I,
Müller-Newen G,
Achaper F,
and
Graeve L.
Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway.
Biochem J
334:
297-314,
1998.
12.
Hirota, H,
Yoshida K,
Kishimoto T,
and
Taga T.
Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice.
Proc Natl Acad Sci USA
92:
4862-4866,
1995
13.
Hou, J,
Baichwal V,
and
Cao Z.
Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1.
Proc Natl Acad Sci USA
91:
11641-11645,
1994
14.
Ikeda, U,
Ohkawa F,
Seino Y,
Yamamoto K,
Hidaka Y,
Kasahara T,
Kawai T,
and
Shimada K.
Serum interleukin 6 levels become elevated in acute myocardial infarction.
J Mol Cell Cardiol
24:
579-584,
1992[ISI][Medline].
15.
Kishimoto, T,
Taga T,
and
Akira S.
Cytokine signal transduction.
Cell
76:
253-262,
1994[ISI][Medline].
16.
Kol, A,
Bourcier T,
Lichtman AH,
and
Libby P.
Chlamydial and human heat shock protein 60S activate human vascular endothelium, smooth muscle cells, and macrophages.
J Clin Invest
103:
571-577,
1999[ISI][Medline].
17.
Kopf, M,
Baumann H,
Freer G,
Freudenberg M,
Lamers M,
Kishimoto T,
Zinkernagel R,
Bluethmann H,
and
Kohler G.
Impaired immune and acute-phase responses in interleukin-6-deficient mice.
Nature
368:
339-342,
1994[Medline].
18.
Kukielka, GL,
Smith W,
Manning AM,
Youker KA,
Michael LH,
and
Entman ML.
Induction of interleukin-6 synthesis in the myocardium: potential role in postreperfusion inflammatory injury.
Circulation
92:
1866-1875,
1995
19.
Kumar, A,
Thota V,
Dee L,
Olson J,
Uretz E,
and
Parrillo JE.
Tumor necrosis factor
and interleukin 1
are responsible for in vitro myocardial cell depression induced by human septic shock serum.
J Exp Med
183:
949-958,
1996
20.
Lamy, M,
and
Deby-Dupont G.
Is sepsis a mediator-inhibitor mismatch?
Intensive Care Med
21:
S250-S257,
1995.
21.
Ramji, DP,
Vitelli A,
Tronche F,
Cortese R,
and
Ciliberto G.
The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP
/NF-IL6
, are induced by IL-6 to promote acute phase gene transcription via different mechanisms.
Nuc Acids Res
21:
289-294,
1993
22.
Ruef, J,
Hu ZY,
Yin LY,
Wu Y,
Hanson SR,
Kelly AB,
Harker LA,
Rao GN,
Runge MS,
and
Patterson C.
Induction of vascular endothelial growth factor in balloon-injured baboon arteries.
Circ Res
81:
24-33,
1997
23.
Saito, H,
Shultz LD,
Sinha M,
and
Papaconstantinou J.
Induction of the
1-antichymotrypsin gene in the brain associated with TGF-
1 deficiency or systemic administration of endotoxin.
Biochem Biophys Res Comm
263:
270-275,
1999[ISI][Medline].
24.
Simpson, P.
Stimulation of hypertrophy of cultured neonatal rat heart cells through an
1-adrenergic receptor and induction of beating through an
1- and
1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating.
Circ Res
56:
884-894,
1985
25.
Smith, CW,
Entman ML,
Lane CL,
Beaudet AL,
Ty TI,
Youker K,
Hawkins HK,
and
Anderson DC.
Adherence of neutrophils to canine cardiac myocytes in vitro is dependent on intercellular adhesion molecule-1.
J Clin Invest
88:
1216-1223,
1991.
26.
Troutt, AB,
and
Lee F.
Tissue distribution of murine hemopoietic growth factor mRNA production.
J Cell Physiol
138:
38-44,
1989[ISI][Medline].
27.
Ulich, TR,
Guo K,
Remick D,
del Castillo J,
and
Yin S.
Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6.
J Immunol
146:
2316-2323,
1991[Abstract].
28.
Xing, Z,
Gauldie J,
Cox G,
Baumann H,
Jordana M,
Lei XF,
and
Achong MK.
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.
J Clin Invest
101:
311-320,
1998[ISI][Medline].
29.
Yamauchi-Takihara, K,
Ihara Y,
Ogata A,
Yoshizaki K,
Azuma J,
and
Kishimoto T.
Hypoxic stress induces cardiac myocyte-derived interleukin-6.
Circulation
91:
1520-1524,
1995
30.
Youker, K,
Smith CW,
Anderson DC,
Miller D,
Michael LH,
Rossen RD,
and
Entman ML.
Neutrophil adherence to isolated adult cardiac myocytes.
J Clin Invest
89:
602-609,
1992.
This article has been cited by other articles:
![]() |
B. M. Meador, C. P. Krzyszton, R. W. Johnson, and K. A. Huey Effects of IL-10 and age on IL-6, IL-1{beta}, and TNF-{alpha} responses in mouse skeletal and cardiac muscle to an acute inflammatory insult J Appl Physiol, April 1, 2008; 104(4): 991 - 997. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Mikaelian, D. Coluccio, K. T. Morgan, T. Johnson, A. L. Ryan, E. Rasmussen, R. Nicklaus, C. Kanwal, H. Hilton, K. Frank, et al. Temporal Gene Expression Profiling Indicates Early Up-regulation of Interleukin-6 in Isoproterenol-induced Myocardial Necrosis in Rat Toxicol Pathol, February 1, 2008; 36(2): 256 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-W. Yu, Q. Chen, R. H Kennedy, and S. J Liu Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes J. Physiol., July 15, 2005; 566(2): 327 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Saito and J. Papaconstantinou Age-associated Differences in Cardiovascular Inflammatory Gene Induction during Endotoxic Stress J. Biol. Chem., July 27, 2001; 276(31): 29307 - 29312. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |